Loading…
Immunotherapy biotech selling Anktiva for bladder cancer and developing cell-therapy and cancer-vaccine candidates.
Immunotherapy biotech selling Anktiva for bladder cancer and developing cell-therapy and cancer-vaccine candidates.
Earns from sales of Anktiva, instilled into the bladder in a urologist's office alongside the standard BCG treatment. Spending far exceeds sales while the launch builds, and the company has been funded largely by chairman Patrick Soon-Shiong, who holds a majority of the shares. The rest of the pipeline is not yet generating sales.
Moat: narrow (IP / patents, regulatory licence). Approved therapy for a specific unmet niche (BCG-unresponsive bladder cancer) ahead of most pipeline rivals.
Headquarters: San Diego, California, United States · Founded: 2014 · Employees: 691
Size ImmunityBio (IBRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $9.15B, the 818th largest of 3,117 United States companies the cockpit tracks. Shares closed at $8.63 on 6 Nov 2026.
Performance Over six months the shares gained 1.5%, against +14.2% for the median peer and -1.1% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue grew 192.9% over the last twelve months (peer median +15.3%); the operating margin is -151.9% (peer median 13.9%).
Valuation It trades at 60.5× enterprise value to sales against a peer median of 6.9× (2nd most expensive of 19).
Short interest Short interest is 11.6% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $166M | $113M | $14.7M | $622,000 | $240,000 |
| Revenue growth | — | +668% | +2,271% | +159% | — |
| Gross profit | $148M | $97.0M | -$2.81M | -$17.9M | -$24.0M |
| EBITDA | -$235M | -$241M | -$327M | -$343M | -$326M |
| Net income | -$992M | -$351M | -$414M | -$583M | -$417M |
| Free cash flow | -$288M | -$309M | -$398M | -$397M | -$416M |
| Capital expenditure | $7.38M | $4.25M | $6.89M | $30.6M | $99.4M |
| Total debt | $1.23B | $845M | $790M | $884M | $725M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| ImmunityBio IBRX | $9.15B | +1% | +193% | -152% | 60.5× | n/a |
| Merck & MRK | $362B | +33% | +5% | 18% | 5.4× | 4.1% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 7.0× | 3.5% |
| UroGen Pharma URGN | $1.21B | -16% | +159% | -12% | 5.2× | n/a |
| CG Oncology CGON | $6.74B | +9% | +1,030% | -4,056% | 917.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IBRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.9% | +5.6% | 6th lowest of 21 |
| 6-month return | +1.5% | +14.2% | 8th lowest of 21 |
| Distance from 52-week high | -30.5% | -14.1% | 5th lowest of 21 |
| Revenue growth (TTM) | +192.9% | +15.3% | highest of 20 |
| Operating margin | -151.9% | 13.9% | 2nd lowest of 19 |
| EV / Sales | 60.5× | 6.9× | 2nd most expensive of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | 60.5× | n/a | n/a |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 11.7× | 50.3% | +426.7% |
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 6.1× | n/a | n/a |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $8.70B | -5% | +8% | 6% | 2.3× | 4.1% | +6.6% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 27.6× | 47.5% | +10.0% |
| Spyre Therapeutics SYRE | United States | $9.86B | +38% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.48B | -7% | +9% | 3% | 0.3× | -10.3% | +7.4% |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $8.19B | +22% | +24% | 17% | 6.8× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $10.2B | -38% | +42% | -25% | 19.5× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 7.8× | 7.6% | +12.6% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 2.0× | -6.1% | +9.3% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | 2.4× | -9.1% | +6.6% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 7.9× | 24.9% | +16.6% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | 27.4× | n/a | n/a |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.73B | +9% | +33% | 20% | 4.1× | 20.0% | +9.4% |
| Alkermes Public ALKS | United States | $7.71B | +31% | +15% | 5% | 4.9× | 31.5% | +7.3% |
| Mankind Pharma MANKIND.NS | India | $11.1B | +7% | +13% | 21% | 7.0× | 27.6% | +18.1% |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 13.6× | 56.4% | +15.0% |
| Grifols GRF.MC | Spain | $7.49B | +23% | 0% | 16% | 2.3× | 6.8% | +7.1% |
| Cytokinetics CYTK | United States | $7.46B | -30% | -21% | -1,046% | 111.8× | n/a | n/a |